Immunocore Holdings plc 6YG.F Stock
Immunocore Holdings plc Price Chart
Immunocore Holdings plc 6YG.F Financial and Trading Overview
| Immunocore Holdings plc stock price | 53 EUR |
| Previous Close | 53 EUR |
| Open | 52 EUR |
| Bid | 52.5 EUR x N/A |
| Ask | 54 EUR x N/A |
| Day's Range | 52 - 52 EUR |
| 52 Week Range | 28 - 64 EUR |
| Volume | 50 EUR |
| Avg. Volume | 3 EUR |
| Market Cap | 2.43B EUR |
| Beta (5Y Monthly) | 0.575598 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.33 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 68.87 EUR |
6YG.F Valuation Measures
| Enterprise Value | 2.29B EUR |
| Trailing P/E | N/A |
| Forward P/E | -39.097744 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 14.644234 |
| Price/Book (mrq) | 9.179171 |
| Enterprise Value/Revenue | 13.84 |
| Enterprise Value/EBITDA | -62.653 |
Trading Information
Immunocore Holdings plc Stock Price History
| Beta (5Y Monthly) | 0.575598 |
| 52-Week Change | 69.87% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 64 EUR |
| 52 Week Low | 28 EUR |
| 50-Day Moving Average | 51.18 EUR |
| 200-Day Moving Average | 52.5 EUR |
6YG.F Share Statistics
| Avg. Volume (3 month) | 3 EUR |
| Avg. Daily Volume (10-Days) | 0 EUR |
| Shares Outstanding | 46.23M |
| Float | 27.99M |
| Short Ratio | N/A |
| % Held by Insiders | 14.68% |
| % Held by Institutions | 69.28% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -25.20% |
| Operating Margin (ttm) | -24.44% |
| Gross Margin | 40.03% |
| EBITDA Margin | -22.089% |
Management Effectiveness
| Return on Assets (ttm) | -7.11% |
| Return on Equity (ttm) | -19.10% |
Income Statement
| Revenue (ttm) | 165.8M EUR |
| Revenue Per Share (ttm) | 3.54 EUR |
| Quarterly Revenue Growth (yoy) | 98.20% |
| Gross Profit (ttm) | 54.11M EUR |
| EBITDA | -36627000 EUR |
| Net Income Avi to Common (ttm) | -41793000 EUR |
| Diluted EPS (ttm) | -1.03 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 337.46M EUR |
| Total Cash Per Share (mrq) | 6.98 EUR |
| Total Debt (mrq) | 68.14M EUR |
| Total Debt/Equity (mrq) | 24.86 EUR |
| Current Ratio (mrq) | 4.558 |
| Book Value Per Share (mrq) | 5.665 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 13.73M EUR |
| Levered Free Cash Flow (ttm) | 18.34M EUR |
Profile of Immunocore Holdings plc
| Country | Germany |
| State | N/A |
| City | Abingdon |
| Address | 92 Park Drive |
| ZIP | OX14 4RY |
| Phone | 44 12 3543 8600 |
| Website | https://www.immunocore.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 408 |
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also developing other programs for oncology comprise tebentafusp that is in Phase 2/3 clinical trial in patients with advanced melanoma; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising cutaneous melanoma, ovarian, non-small cell lung cancer, and endometrial; IMC-T119C for multiple solid tumor cancers; IMC-P115C for multiple solid tumor cancers; and IMC-R117C, which is for a range of tumors, including colorectal, gastro-esophageal, and pancreatic cancers. In addition, the company's programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in Phase 1 clinical trial for patients with human immunosuppression virus. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
Q&A For Immunocore Holdings plc Stock
What is a current 6YG.F stock price?
Immunocore Holdings plc 6YG.F stock price today per share is 53 EUR.
How to purchase Immunocore Holdings plc stock?
You can buy 6YG.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Immunocore Holdings plc?
The stock symbol or ticker of Immunocore Holdings plc is 6YG.F.
Which industry does the Immunocore Holdings plc company belong to?
The Immunocore Holdings plc industry is Biotechnology.
How many shares does Immunocore Holdings plc have in circulation?
The max supply of Immunocore Holdings plc shares is 49.82M.
What is Immunocore Holdings plc Price to Earnings Ratio (PE Ratio)?
Immunocore Holdings plc PE Ratio is now.
What was Immunocore Holdings plc earnings per share over the trailing 12 months (TTM)?
Immunocore Holdings plc EPS is -1.33 EUR over the trailing 12 months.
Which sector does the Immunocore Holdings plc company belong to?
The Immunocore Holdings plc sector is Healthcare.